All In Biotech

Drug Trial Radar · NCT01794793

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

337

Actual

Start

Jun 10, 2013

Primary completion

Jul 25, 2023

Study completion Jul 25, 2023

Sponsor

Lead sponsor
RECORDATI GROUPIndustry
Sponsor type
Industry
First posted
Feb 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.

Conditions

  • Cushing's Disease
  • Acromegaly
  • Neuroendocrine Tumors
  • Pituitary Tumors
  • Ectopic ACTH Secreting (EAS) Tumors
  • Dumping Syndrome
  • Prostate Cancer
  • Melanoma Negative for bRAF
  • Melanoma Negative for nRAS

Interventions

  • PasireotideDrug

    Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

  • CabergolineDrug

    Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.

  • Pasireotide LARDrug

    Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events to Evaluate Long Term Safety DataTime frame: Baseline up to approximately 10 years

Locations

94 sites in 28 countries. Site status is shown where the registry gives one.

  • Ximed Research SC - SOM230B2412

    La Jolla, California

  • Cedars Sinai Medical Center Cedars Sinai 4

    Los Angeles, California

  • Stanford Universtiy Medical Center Stanford Hospital & Clinics

    Stanford, California

  • University of Michigan Comprehensive Cancer Center SC-2

    Ann Arbor, Michigan

  • Memorial Sloan-Kettering Cancer Center SC

    New York, New York

  • Virginia Endocrinology Research SC

    Chesapeake, Virginia

  • Swedish Cancer Institute Swedish Cancer Institute (SC)

    Seattle, Washington

  • Recordati Investigative Site

    CABA, Buenos Aires, Argentina

  • Recordati Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Recordati Investigative Site

    Bruges, Belgium

  • Recordati Investigative Site

    Brussels, Belgium

  • Recordati Investigative Site

    Brussels, Belgium

  • Recordati Investigative Site

    Ghent, Belgium

  • Recordati Investigative Site

    Leuven, Belgium

  • Recordati Investigative Site

    Liège, Belgium

  • Recordati Investigative Site

    Wilrijk, Belgium

  • Recordati Investigative Site

    Edegem, Antwerpen, Belgium

  • Recordati Investigative Site

    Fortaleza, Ceará, Brazil

  • Recordati Investigative Site

    Curitiba, Paraná, Brazil

  • Recordati Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Recordati Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Recordati Investigative Site

    Joinville, Santa Catarina, Brazil

  • Recordati Investigative Site

    Botucatu, São Paulo, Brazil

  • Recordati Investigative Site

    São Paulo, São Paulo, Brazil

  • Recordati Investigative Site

    Sofia, Bulgaria

  • Recordati Investigative Site

    Halifax, Nova Scotia, Canada

  • Recordati Investigative Site

    London, Ontario, Canada

  • Recordati Investigative Site

    Montreal, Quebec, Canada

  • Recordati Investigative Site

    Montreal, Quebec, Canada

  • Recordati Investigative Site

    Angers, France

  • Recordati Investigative Site

    Bron, France

  • Recordati Investigative Site

    Le Kremlin-Bicêtre, France

  • Recordati Investigative Site

    Lille, France

  • Recordati Investigative Site

    Marseille, France

  • Recordati Investigative Site

    Pessac, France

  • Recordati Investigative Site

    Pierre-Bénite, France

  • Recordati Investigative Site

    Toulouse, Cedex 9, France

  • Recordati Investigative Site

    Berlin, Germany

  • Recordati Investigative Site

    Hamburg, Germany

  • Recordati Investigative Site

    München, Germany

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.